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Activin-like kinase 3  
is important for kidney  
regeneration and  
reversal of fibrosis
Sugimoto et al., Nat Med 2012; 18: 396–404; doi:10.1038/nm.2629
The Holy Grail of chronic progressive kidney disease is to 
halt (or reverse) fibrosis. The transforming growth factor 
(TGF) family of cytokines plays an important role in promot-
ing fibrosis. Two members of this family are important in this 
respect: TGF-b promotes fibrosis, and bone morphogenic 
protein 7 (BMP7) is an antagonist to TGF-b and prevents 
or reverses fibrosis. BMP7 acts via its receptor, activin-like 
kinase 3 (Alk3), which is found on tubular epithelial cells. 
In this study, the levels of BMP7 and Alk3 were found to be 
inversely correlated with progression of fibrosis. Deletion of 
the Alk3 receptor was associated with worsening fibrosis fol-
lowing renal injury. A peptide agonist of Alk3, THR-123, was 
engineered and was found to specifically suppress inflam-
mation, apoptosis, and epithelial-to-mesenchymal transfor-
mation (events that precede fibrosis) in five mouse models 
of renal disease: renal ischemia, Alport’s disease, diabetic 
nephropathy, ureteral obstruction, and nephrotoxic nephri-
tis. Consequently, fibrosis was substantially reversed in all 
these models.
The Figure demonstrates improvement in tubular atrophy 
and interstitial fibrosis with THR-123, which was adminis-
tered between weeks 6 and 9 of renal injury in the nephro-
toxic nephritis model. Importantly, this protective effect was 
additive to that of angiotensin-converting enzyme inhibitors. 
BMP agonists via the Alk3 receptor appear to hold promise 
in reversing renal fibrosis and merit further study.
Jai Radhakrishnan
Trajectories of kidney function 
decline in the 2 years before 
initiation of long-term dialysis
O’Hare et al., Am J Kidney Dis 2012; 59: 513–522; doi:10.1053/j.
ajkd.2011.11.044
The ethos of the modern-day management of patients with pro-
gressive chronic kidney disease is to retard the underlying rate 
of progression of kidney disease and predict the need for renal 
replacement therapy, such that preemptive transplantation can 
occur for those fortunate enough to have a suitable living donor, 
or timely arteriovenous fistula formation or peritoneal dialy-
sis catheter insertion can take place for those choosing dialytic 
modes of therapy. Prediction of the need for dialysis has been 
based traditionally on reciprocal or log serum creatinine plots, 
and now on estimated glomerular filtration rate (eGFR), with 
the assumption that the decline in renal function is essentially 
linear, although sometimes interspersed with episodes of acute 
decompensation, with or without recovery. In their study, O’Hare 
and colleagues challenged this traditional paradigm of the time 
course of progressive kidney disease and prospectively followed 
more than 5600 chronic kidney disease patients before initia-
tion of renal replacement therapy. Rather than using the tradi-
tional longitudinal models of changes in renal function, which 
were designed to describe average effects, they used trajectory 
modeling to identify distinct patterns of change within a popu-
lation and estimate the probability of any individual’s following 
a trajectory pattern. By this technique, four basic patterns were 
identified, ranging from relatively stable but low eGFR to slowly 
progressive loss of eGFR through faster and finally rapid loss-of-
function trajectories. Interestingly, those with the faster declines 
tended to be younger patients, whereas those with the traditional 
risk factors of hypertension, proteinuria, and diabetes were pre-
dominantly in the two slower progression groups.
This study highlights that the time course of progressive kidney 
disease varies. Thus it must be assessed on an individual basis so 
that patients receive appropriate counseling and arteriovenous 
fistulae and peritoneal dialysis catheters are placed in a timely 
fashion—not too early and not too late.
Andrew Davenport
A size-exclusion permeability 
barrier and nucleoporins 
characterize a ciliary pore complex 
that regulates transport into cilia
Kee et al., Nat Cell Biol 2012; 14: 431–437; doi:10.1038/ncb2450
Cystic diseases of the kidney belong to the group of ciliopathies, 
a wide range of affections due to alteration of the proteins 
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THR-123 reverses renal fibrosis in mice with nephrotoxic nephritis. 
Morphometric analysis from control mice (n = 5), mice at 1 week (n = 6), 3 
weeks (n = 8), and 6 weeks after induction of nephrotoxic nephritis (NTN) 
(n = 6), and mice at 9 weeks after NTN that were given THR-123 starting at 6 
weeks after NTN (THR-123 (6–9 weeks); n = 6) assessing the percentage of 
glomerulosclerosis score (left), tubular atrophy index (middle), and fibrosis 
index (right).
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belonging to the primary cilium, a microtubule-based orga-
nelle with important cellular functions, such as regulation of 
development, cell mechanosensation, and detection of fluid 
flow. In recent years, a number of studies have dissected several 
properties of the primary cilium, including its unique protein 
and lipid makeup, which is synthesized in the cell cytoplasm 
and specifically targeted to the organelle. The cilium lacks a 
limiting membrane; therefore, its ‘selection point’ is consid-
ered to be a specialized area at the base of the organelle called 
the transition zone. But the molecular mechanisms affecting 
selectivity remain to be completely uncovered. Kee et al. add 
important information to this field of investigation. Previous 
findings by the same group demonstrated that components of 
the nuclear import machinery are involved in regulating the 
entry of specific proteins into the cilium. Here, they extend 
these observations, showing that the base of the cilium con-
tains a ciliary pore complex that is similar to the nuclear pore 
complex. The nuclear pore complex (Figure) is an assembly of 
proteins forming a pore-like structure, that regulates nuclear-
cytoplasmic shuttling. A size-exclusion mechanism limits the 
passage of molecules with a relative molecular mass higher 
than 30,000, and nuclear localization signal (NLS) proteins 
regulate the passage of proteins of greater size. By intracellular 
microinjection of labeled dextrans, the authors first describe a 
size-dependent diffusion barrier at the primary cilium. Then, 
by combining transfection experiments with immunostaining 
of endogenous proteins, they show the expression of defined 
nucleoporins at the base of the primary cilium and demonstrate 
that nucleoporin blockade indeed inhibits the ciliary transport 
of the kinesin-2 motor KIF17.
Additional study to clarify the mechanisms used to dis-
tinguish between nuclear and ciliary cargoes and a complete 
elucidation of the molecular network at the base of the cilium 
would seem to be a promising way to understand the complex 
biology of this organelle and its related diseases.
Maria Pia Rastaldi
Claudin-14 regulates renal  
Ca++ transport in response  
to CaSR signaling via a novel 
microRNA pathway
Gong et al., EMBO J advance online publication, 28 February 2012, 
doi:10.1038/emboj.2012.49
Claudins are proteins that are important components of inter-
cellular tight junctions and have many functions, including 
regulation of cell morphology, intercellular signaling, and par-
acellular molecular transport. Claudins-16 and -19 are exclu-
sively expressed in the thick ascending limb (TAL) of Henle, 
and though mutations in the genes encoding these proteins are 
known to underlie the pathogenesis of familial hypomagnesemia 
with hypercalciuria and nephrocalcinosis, the mechanism by 
which they regulate magnesium and calcium reabsorption 
in the TAL remains controversial. Similarly, variations in the 
claudin-14 gene have recently been found to be associated with 
increased risk of hypercalciuric nephrolithiasis, although the 
function of claudin-14 is unknown. Gong et al. found that 
claudin-14 is expressed exclusively in the TAL and that clau-
din-14 mRNA is targeted by microRNAs, miR-9 and miR-374, 
which increase degradation and inhibit translation of claudin-14 
mRNA in mice fed a normal diet. However, in mice fed a high-
calcium diet, expression of miR-9 and miR-374 decreases and 
claudin-14 expression increases in the TAL. In vitro studies 
further demonstrated that expression of the calcium-sensing 
receptor (CaSR) is necessary for high extracellular calcium to 
suppress expression of miR-9 and miR-374 and, conversely, to 
increase levels of claudin-14 in TAL cells. The authors also found 
that claudin-14 interacts with claudins-16 and -19 and that cells 
coexpressing claudin-14 with claudins-16 and -19 have reduced 
cation selectivity compared with cells expressing claudins-16 
and -19 without claudin-14. Importantly, these in vitro studies 
were supported by the observation that claudin-14 knockout 
mice develop hypermagnesemia, hypomagnesiuria, and hypo-
calciuria when fed a high-calcium diet.
This study is the first to identify a direct role and mechanism 
for claudin-14 in regulating cation reabsorption in the kidney 
and therefore advances our understanding of how calcium and 
magnesium are handled within the kidney. However, further 
research is needed to determine whether mutations in clau-
din-14 that are associated with increased risk of hypercalciu-
ric nephrolithiasis alter the ability of miR-9 and miR-374 to 
regulate claudin-14 expression.
Michael Ross
The overall structure and subcomplexes of the NPC. 
FG, phenylalanine-glycine; NPC, nuclear pore complex;  
NUP, nucleoporin.
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